natgillin/translations-raw huggingface dataset:
If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part 
Če želite več informacij o podlagi za priporočila CHMP, preberite znanstveno razpravo (ki je prav
Exubera is given within 10 minutes before the start of a meal. 
Zdravilo Exubera dajemo v roku 10 minut pred obrokom.
Smokers must have stopped smoking for at least 6 month before they can take Exubera. 
Kadilci morajo prenehati s kajenjem vsaj 6 mesecev preden lahko uporabijo zdravilo Exubera.
The company will also monitor side effects, provide educational material, and improve the design of the blister packs so that it is easier to tell the 
Podjetje bo tudi spremljalo neželene učinke, priskrbelo izobraževalno gradivo in izboljšalo zasnovo pretisnih omotov, da bo lažje
So Exubera is not suitable when small (less than 3 IU) adjustments of insulin are necessary (for example in patient with low body weight). 
Zato zdravilo Exubera ni primerno, kadar so potrebna majhna (manj kot 3 ME) prilagajanja insulina (na primer pri bolniku z nizko telesno maso).
They will also look at the development of insulin antibodies (proteins that are produced in response to treatment with Exubera). 
Raziskali bodo tudi razvoj protiteles proti insulinu (beljakovine, ki nastajajo kot odziv na zdravljenje z zdravilom Exubera).
By controlling the level of blood sugar, the symptoms and complications of diabetes are reduced. 
Z nadzorom ravni krvnega sladkorja se zmanjšajo simptomi in zapleti sladkorne bolezni.
A doctor decides for each patient the starting doses and the timing of the doses, and the dose adjustment schedule. 
Zdravnik za vsakega bolnika določi začetni odmerek, časovni razpored odmerkov ter načrt prilagajanja le-teh.
The company that makes Exubera will carry out studies to further test its safety, particularly in patients who might have an increased risk of side effects, such as patients with asthma or chronic obstructive pulmonary disease. 
Podjetje, ki izdeluje zdravilo Exubera, bo opravilo raziskave za nadaljnje preskušanje njene varnosti, zlasti pri bolnikih, ki bi lahko imeli povečano tveganje za neželene učinke, kot so bolniki z astmo ali kronično obstruktivno pljučno boleznijo.
Before starting Exubera, a doctor or a nurse must explain to the patient how to use the inhaler properly to minimise risk and ensure that the patient gets the best benefit from their treatment. 
Pred začetkom uporabe zdravila Exubera mora bolniku zdravnik ali medicinska sestra razložiti, kako pravilno uporabljati inhalator, da se zmanjša tveganje in zagotovi, da je zdravljenje čimbolj koristno.
When inhaled, some of the insulin is absorbed into the blood (the rest is broken down in the lungs). 
Ob vdihovanju se nekaj insulina absorbira v kri (preostanek se razgradi v pljučih).
Patients with poor or unstable lung function, such as asthma, emphysema or chronic bronchitis, should not use Exubera. 
Bolniki s slabo ali nestabilno pljučno funkcijo, denimo, z astmo, emfizemom ali kroničnim bronhitisom, zdravila Exubera ne smejo uporabljati.
The insulin in Exubera is produced by a method known as ‘recombinant DNA technology' which means that the insulin is made by a bacterium which has received a gene (DNA) that makes it able to produce the insulin. 
Insulin v zdravilu Exubera je izdelan z metodo, imenovano ‘tehnologija rekombinantne DNA', kar pomeni, da insulin izdeluje bakterija, ki je prejela gen (DNA), ki ji omogoča izdelovanje insulina.
If a patient already has lung disease, it is not clear how the use of Exubera affects their lungs or how the lung disease affects the intake of insulin from the lungs. 
Če bolnik že ima pljučno obolenje, ni jasno, kako uporaba zdravila Exubera vpliva na pljuča ali kako pljučna bolezen vpliva na vnos insulina iz pljuč.
If a patient smokes, the amount of insulin that is absorbed from the lungs greatly increases and this may increase the risk of hypoglycaemia. 
Če bolnik kadi, se količina insulina, ki se absorbira iz pljuč, močno poveča, kar lahko poveča nevarnost za hipoglikemijo.
Once in the blood, the insulin facilitates the transport of glucose into cells and helps to control the level of blood sugar. 
Ko je enkrat v krvi, insulin pospešuje transport glukoze v celice in pomaga nadzorovati raven krvnega sladkorja.
Three 1 mg doses should not be used instead of one 3 mg dose because this gives a higher insulin dose and may increase the risk of hypoglycaemia. 
Namesto enega 3 mg odmerka ne smemo uporabiti treh odmerkov po 1 mg, ker to pomeni višji odmerek insulina in lahko poveča nevarnost za hipoglikemijo.
The Committee for Medicinal products for Human Use (CHMP) decided that Exubera's benefits are greater than its risks in certain adult patients with diabetes when used as described in the Product information, and recommended that Exubera be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) meni, da koristi zdravila Exubera presegajo njena tveganja pri določenih odraslih bolnikih s sladkorno boleznijo ob uporabi, kot je opisano v Navodilu za uporabo, zato priporoča odobritev dovoljenja za promet z zdravilom Exubera.
Diabetes is a disease in which the body does not produce enough insulin to control the level of blood sugar. 
Sladkorna bolezen je bolezen, pri kateri telo ne izdeluje dovolj insulina, da bi obvladovalo raven krvnega sladkorja.
To take a dose, the patient places the blister in the inhaler, and inhales it through the mouth into the lungs. 
Da dobi odmerek, bolnik položi pretisni omot v inhalator in ga prek ust vdihne v pljuča.
The most common side effects of Exubera are hypoglycaemia (low blood glucose) and cough. 
Najpogostejša neželena učinka zdravila Exubera sta hipoglikemija (nizka raven glukoze v krvi) in kašelj.
During the studies, Exubera showed a small negative effect on lung function that may disappear when Exubera is stopped. 
V raziskavah je Exubera pokazala majhen negativni učinek na pljučno funkcijo, ki lahko po prenehanju uporabe zdravila Exubera izzveni.
If a patient starts or resumes smoking when treated with Exubera, they must use another anti-diabetic treatment immediately. 
Če bolnik začne kaditi ali ponovno začne kaditi med zdravljenjem z zdravilom Exubera, mora takoj zamenjati zdravilo Exubera za drugo antidiabetično zdravljenje.
The studies measured the level in the blood of glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled. 
V raziskavah so merili raven glikoziliranega hemoglobina (HbA1c) v krvi, kar nam pove, kako dobro je raven glukoze v krvi nadzorovana.
What benefit has Exubera shown during the studies? 
Kakšne koristi je zdravilo Exubera izkazalo med raziskavami?
Exubera is an insulin used for the treatment of adults with type 2 diabetes, when it is not properly controlled with anti-diabetes tablets. 
Exubera je insulin, ki ga uporabljamo za zdravljenje odraslih bolnikov s sladkorno boleznijo tipa 2, kadar ta ni ustrezno nadzorovana z uporabo antidiabetičnih tablet.
How has Exubera been studied? 
Kako je bilo zdravilo Exubera raziskano?
Exubera contains 1 mg or 3 mg of 
Exubera vsebuje 1 mg ali 3 mg zdravilne učinkovine humanega insulina.
What is the risk associated with Exubera? 
Kakšna tveganja so povezana z zdravilom Exubera?
A 1 mg unit dose blister gives about the same dose as an injection of 3 IU of fast-acting subcutaneous insulin and a 3 mg unit dose blister about the same as 8 IU of fast-acting subcutaneous insulin. 
Pretisni omot z odmerkom 1 mg zagotovi enak odmerek kot podkožno injiciranje 3 ME hitrodelujočega insulina, pretisni omot z odmerkom 3 mg zagotovi približno tak odmerek kot podkožno injiciranje 8 ME hitrodelujočega insulina.
Exubera is a fast-acting insulin powder for inhalation (breathing in). 
Exubera je hitrodelujoči insulin v obliki praška za inhaliranje (vdihovanje).
Patients must not smoke while taking Exubera. 
Bolniki med jemanjem zdravila Exubera ne smejo kaditi.
Exubera is used only with its insulin inhaler. 
Zdravilo Exubera uporabljamo samo skupaj z njegovim insulinskim inhalatorjem.
Overall, in studies in type 1 and type 2 diabetes, Exubera gave similar blood glucose control to that given by fast-acting subcutaneous human insulin. 
V splošnem je v raziskavah sladkorne bolezni tipa 1 in 2 zdravilo Exubera omogočalo podoben nadzor ravni krvnega sladkorja, kot ga daje hitrodelujoči podkožni humani insulin.
Exubera can also be used for certain adults with type 1 diabetes, who can benefit from replacing fast-acting subcutaneous insulin by this inhaled insulin, taking into 
Zdravilo Exubera lahko uporabljamo tudi za določene odrasle bolnike s sladkorno boleznijo tipa 1, za katere je lahko ob upoštevanju možnih tveganj, koristna zamenjava hitrodelujočega insulina, ki se injicira pod kožo, s
Exubera has been studied in patients with type 2 or type 1 diabetes. 
Zdravilo Exubera so preučevali pri bolnikih s sladkorno boleznijo tipa 1 ali 2.
Exubera should not be used in people who may be hypersensitive (allergic) to human insulin or any of 
Zdravila Exubera ne smejo uporabljati ljudje, ki utegnejo biti preobčutljivi za (alergični na) humani
Exubera is a replacement insulin which is identical to the insulin made by the pancreas. 
Exubera je nadomestni insulin, ki je enak insulinu, ki ga izdeluje trebušna slinavka.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EXUBERA EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) EXUBERA
The insulin is contained as a powder in a blister. 
Insulin je v obliki praška in je pakiran v pretisnem omotu.
Exubera works in type 1 diabetes, when the pancreas cannot produce enough insulin, and in type 2 diabetes when the body is unable to use insulin effectively. 
pri sladkorni bolezni tipa 1, ko trebušna slinavka ne more izdelati dovolj insulina, in pri sladkorni bolezni tipa 2, ko telo ni zmožno učinkovito uporabljati insulina.
In type 1 diabetes, Exubera was compared to subcutaneous (injected) insulin. 
Pri sladkorni bolezni tipa 1 so zdravilo Exubera primerjali s podkožnim (injiciranim) insulinom.
In type 2 diabetes, Exubera was compared to subcutaneous insulin, and to oral anti-diabetes medicines. 
Pri sladkorni bolezni tipa 2 so Exubero primerjali s podkožnim insulinom in s peroralnimi antidiabetičnimi sredstvi.
What are the measures to minimise the risk associated with Exubera? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Exubera?
For the full description of the side effects reported with 
Celovit opis možnih neželenih učinkov, o katerih so poročali pri uporabi zdravila Exubera, najdete v
Member State Marketing Authorisation Holder Applicant 
Država članica Imetnik dovoljenja za promet
On 30 November 2006, the application has been referred and submitted for arbitration according to Article 29 of Directive 2001/83/EC, as amended. 
30. novembra 2006 je bila vloga predana in predložena v presojo skladno s členom 29 Direktive 2001/83/EC, s spremembami.
78-110%) were outside the conventional limits they comply with the wider 75-133% criterion. 
78 do 110 %), nahajale zunaj običajnih meja, pa izpolnjujejo zahteve širšega merila, ki se nahaja v območju od 75 do 133 %.
The CHMP has recommended the granting of the Marketing Authorisation(s). 
CHMP je priporočil odobritev dovoljenja za promet z zdravilom(i).
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LANSOPRAZOLE AND ASSOCIATED NAMES (see Annex I) 
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA LANSOPRAZOL IN Z NJIM POVEZANIH IMEN (glejte Dodatek I)
In September 2006, a Mutual Recognition Procedure was started for Lansoprazole involving 16 CMS with the UK as Reference Member State (RMS). 
Septembra leta 2006 se je za zdravilo Lansoprazol začel postopek medsebojnega priznavanja, v katerega je vključenih 16 zadevnih držav članic in Združeno kraljestvo kot referenčna država članica.
It also has a flat dose/response curve i.e. its efficacy is largely independent of the dose. 
Poleg tega je pri njem krivulja odmerek/odziv izravnana, to pomeni, da je njegova učinkovitost v veliki meri neodvisna od odmerka.
Documentation presented to the CHMP shows that the test and reference products are essentially similar. 
Dokumentacija, predložena Odboru za zdravila za uporabo v humani medicini (CHMP), kaže, da sta si testno zdravilo in referenčno zdravilo bistveno podobna.
Lansoprazole has a wide therapeutic window regarding its clinical efficacy and safety. 
Zdravilo Lansoprazol ima veliko terapevtsko širino kar zadeva njegovo klinično učinkovitost in varnost.
This is supported by two similar fed studies using the same reference drug and the same test drug with the same batch number when entirely different results are obtained and which confidence intervals were within conventionally acceptable limits. 
To je podprto z dvema podobnima študijama pri bolnikih, ki so zdravilo jemali na poln želodec, pri katerih je bilo uporabljeno enako referenčno zdravilo in enako testno zdravilo z enako serijsko številko, prišlo pa je do popolnoma različnih rezultatov, intervali zaupanja pa so se nahajali znotraj običajno sprejemljivih meja.
The RMS approved the product on the basis of the results of the fasted study showed unequivocal equivalence as shown by the 90% confidence intervals (CI) for the AUC and Cmax which were within the conventional 80-125% bioequivalence range. 
Referenčna država članica je zdravilo odobrila na osnovi rezultatov študije, v kateri so bolniki zdravilo jemali na tešče, in pri kateri se je pokazala nedvoumna enakovrednost, kar se izkazuje z 90 % intervalom zaupanja (CI) za površino pod krivuljo (AUC) in Cmaks, ki sta se nahajali znotraj običajnega 80 do 125- odstotnega območja biološke enakovrednosti.
The Applicant has provided sufficient data to support that the outcome of the fed study does not lead to a potential risk to public health. 
Priskrbel je dovolj podatkov v podporo temu, da izid študije, v kateri so bolniki zdravilo jemali na poln želodec, nima za posledico morebitnih tveganj za javno zdravje.
This is a known pharmacokinetic characteristic of Lansoprazole, particularly when taken with high fat and calorie meal as in the current case. 
To je znana farmakokinetična lastnost zdravila Lansoprazola, še posebno če se ga jemlje skupaj s hrano, ki vsebuje veliko maščob in kalorij, kot v tem primeru.
Both products show pronounced food effect although the generic product appears to be more affected largely because of the high intra-subject variability. 
Pri obeh zdravilih je vpliv hrane izrazit, čeprav se zdi, da je ta vpliv pri generičnem zdravilu še večji, zaradi velike variabilnosti znotraj posameznih bolnikov.
In conclusion, the questions have been addressed satisfactorily by the applicant. 
Mogoče je sklepati, da se je vlagatelj reševanja vprašanj lotil na zadovoljiv način.
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS / MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE, PREDLAGATELJEV, IMETNIKOV DOVOLJENJA ZA PROMET V DRŽAVAH ČLANICAH
The results were also considered acceptable on clinical grounds as lansoprazole's efficacy is largely independent of dose at this therapeutic dose range. 
Poleg tega so rezultate obravnavali kot sprejemljive na kliničnih temeljih, saj je v tem razponu terapevtskih odmerkov učinkovitost lansoprazola v veliki meri neodvisna od odmerka.
This means that the small difference in blood levels between the reference and test products shown under fed conditions is of no clinical significance. 
Iz tega izhaja, da majhna razlika v koncentracijah v krvi med referenčnim in testno zdravilom, ki so jo ugotovili v razmerah, ko so bolniki zdravilo jemali na poln želodec, nima nobenega kliničnega pomena.
The results of these fed studies demonstrate that Lansoprazole's bioavailability is not only markedly reduced when taken with food, but that its absorption, in the presence of food, can be very erratic. 
Rezultati teh študij pri bolnikih, ki so zdravilo jemali na poln želodec, kažejo, da biološka razpoložljivost zdravila Lansoprazola, kadar se ga jemlje skupaj s hrano, ni samo znatno manjša, temveč da je v prisotnosti hrane lahko zelo neurejena.
Lansoprazole is a proton pump inhibitor that inhibits gastric acid secretion and is used for the treatment of duodenal and benign gastric ulcers, gastrooesophageal reflux disease and associated conditions. 
Lansoprazol je zaviralec protonske črpalke, ki zavira izločanje želodčne kisline in se uporablja za zdravljenje razjed v dvanajstniku in benignih razjed v želodcu, za zdravljenje gastroezofagealne refluksne bolezni in s tem povezanih bolezenskih stanj.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure as mentioned in Annex III. 
Veljavni Povzetek glavnih značilnosti zdravila, označevanje in Navodilo za uporabo zdravila so končne različice, ki so bile pripravljene med postopkom Skupine za usklajevanje, kot je omenjeno v Dodatku III.
It was considered that this wider criterion can be applied in this case because of the extremely high intra-subject variability (70- 82%) under fed conditions shown in this study. 
Prisotno je bilo mnenje, da se zaradi izredno velike variabilnosti znotraj posameznih bolnikov (70 do 82 %), ki se je v tej študiji pokazala v razmerah, ko so bolniki zdravilo jemali na poln želodec, v tem primeru lahko uporabi to širše merilo.
Lansoprazole 15 & 30 mg gastro-resistant capsules, hard (Teva UK Ltd) are generic preparations containing lansoprazole as the active substance. 
Lansoprazol 15 mg in 30 mg gastrorezistentne trde kapsule (Teva UK Ltd) sta generični zdravili, ki vsebujeta zdravilno učinkovino lansoprazol.
The objecting Concerned Member States raised public health objections on the grounds that while bioequivalence was proven in the fasting state, the same was not the case under fed conditions. 
Zadevne države članice, ki so nasprotovale, so z utemeljitvijo, da je bila biološka enakovrednost dokazana pri bolnikih, ki so zdravilo jemali na tešče, ni pa bila dokazana pri bolnikih, ki so zdravilo jemali na poln želodec, opozorile na zadržke, povezane z javnim zdravjem.
Although the CI for the fed study results (CI for AUCinf. 
Čeprav so se vrednosti intervala zaupanja (CI) pri rezultatih študije, v kateri so bolniki zdravilo jemali na poln želodec (CI za AUCinf.
Date of first authorisation: 16 November 2004 Date of latest renewal: 18 July 2014 
Datum prve odobritve: 16. november 2004 Datum zadnjega podaljšanja: 18. julij 2014
They are marked with ‘S 063'. 
Označene so z ‘S 063'.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision. 
Imetnik tega dovoljenja za promet z zdravilom mora obvestiti Evropsko komisijo o načrtu trženja za zdravilo, odobreno s to odločbo.
The bottle also contains a small sealed container. 
Steklenica vsebuje tudi majhen zatesnjen vsebnik.
• If you have or think you might have a problem with your heart; 
• če imate ali mislite, da imate težavo s srcem;
Therefore platelets should be monitored frequently. 
Zato je treba krvne ploščice pogosto spremljati.
9/l or a ≥ 50% reduction from baseline and maintenance of the reduction for at least 4 weeks. 
9/l ali ≥ 50 % zmanjšanje od prvotne vrednosti in ohranitev zmanjšanja vsaj štiri tedne.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list)) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Tell your doctor if you are pregnant or are planning to become pregnant. 
Povejte zdravniku, če ste noseči ali načrtujete nosečnost.
Within the system organ classes they are listed under the following headings: Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Navedeni so po organskih sistemih z naslednjimi opisi pogostnosti: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1000 do < 1/100); redki (≥ 1/10000 do < 1/1000); zelo redki (< 1/10000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
However, as expected, patients in this age group had twice the incidence of serious adverse events (mainly cardiac). 
Kot je bilo pričakovano, so bolniki v tej starostni skupini dvakrat pogosteje doživljali hude težave (v glavnem s srcem).
If you are worried, speak to your doctor. 
Če vas skrbi, se pogovorite s svojim zdravnikom.
• The effects of food on bioavailability are not considered clinically relevant to the use of anagrelide. 
• Učinki hrane na biološko uporabnost niso klinično relevantni za uporabo anagrelida.
After this time, your doctor may either increase or decrease the number of capsules that you take to find the dose best suited to you and which treats your condition most effectively. 
Po tem obdobju vam utegne zdravnik povečati ali zmanjšati število kapsul, da odkrije odmerek, ki vam najbolj ustreza in ki je najbolj učinkovit za vašo bolezen.
Xagrid or these medicines may not work properly if taken together. 
Zdravilo Xagrid ali ta zdravila morda ne bodo imela pravega učinka, če jih boste jemali skupaj.
Food also decreased the Cmax of the active metabolite, 3-hydroxyanagrelide, by 29%, although it had no effect on the AUC. 
Hrana je tudi zmanjšala Cmax aktivnega presnovka, 3-hidroksi-anagrelida, za 29 %, čeprav ni imela vpliva na AUC.
An opaque white hard capsule imprinted with S 063. 
Bela neprozorna trda kapsula z natisnjeno oznako S 063.
The dose increment must not exceed more than 0.5 mg/day in any one-week and the recommended maximum single dose should not exceed 2.5 mg (see section 4.9). 
Povišanje odmerka ne sme presegati več kot 0,5 mg dnevno v katerem koli tednu, priporočen najvišji enkratni odmerek pa ne sme preseči 2,5 mg (glejte poglavje 4.9).
It is not recommended in patients with elevated transaminases (> 5 times the upper limit of normal) (see sections 4.2 and 4.3). 
Ni priporočljivo pri bolnikih s povišanimi ravnmi transaminaz (> 5-krat večje od zgornje meje normale) (glejte poglavji 4.2 in 4.3).
Discontinuation of treatment should be considered in paediatric patients who do not have a satisfactory treatment response after approximately 3 months. 
Prekinitev zdravljenja pride v poštev pri pediatričnih bolnikih, ki se po približno 3 mesecih ne odzovejo zadovoljivo na zdravljenje.
Adverse reactions arising from clinical studies, post-authorisation safety studies and spontaneous reports are presented in the table below. 
Neželeni učinki zdravila, opisani v kliničnih študijah, študijah varnosti po odobritvi zdravila in spontanih poročilih, so predstavljeni v spodnji preglednici.
Linearity Dose proportionality has been found in the dose range 0.5 mg to 2 mg. 
Linearnost Proporcionalnost odmerku so ugotovili v razponu odmerkov od 0,5 mg do 2 mg.
There are limited pharmacokinetic data for this patient population. 
Za to skupino bolnikov so na voljo omejeni farmakokinetični podatki.
In a two-year rat carcinogenicity study, non-neoplastic and neoplastic findings were observed and related or attributed to an exaggerated pharmacological effect. 
V dvoletni raziskavi karcinogenosti pri podganah, so opazovali ne-neoplastične in neoplastične ugotovitve ter jih povezali ali pripisovali prekomernemu farmakološkemu učinku.
Pharmacokinetic data from healthy subjects established that food decreases the Cmax of anagrelide by 14%, but increases the AUC by 20%. 
Farmakokinetični podatki, pridobljeni od zdravih oseb, dokazujejo, da hrana zmanjša Cmax anagrelida za 14 %, a zveča AUC za 20 %.
The disease may progress to myelofibrosis or AML. 
Bolezen lahko napreduje v mielofibrozo ali AML.